Prev Close | 125.05 |
Open | 125.50 |
Day Low/High | 122.12 / 129.80 |
52 Wk Low/High | 6.26 / 189.40 |
Volume | 2.45M |
Prev Close | 125.05 |
Open | 125.50 |
Day Low/High | 122.12 / 129.80 |
52 Wk Low/High | 6.26 / 189.40 |
Volume | 2.45M |
Exchange | NASDAQ |
Shares Outstanding | 63.66B |
Market Cap | 8.15B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
I think BA returns to normal as we do, as the airlines do... but with the defense contracting business as a foundation to rely upon.
Can corporate America grow sales for the fourth quarter? Then answer a question with a question.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Penny stocks are for suckers, and six other rules for better investing -- and tuning out the tweet noise.
Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
Short-term traders may want to nail down profits and be careful in their trading strategy with this name.
Isaac Newton's first lesson: An object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force.
The performance of IWM is telling you that all is not well in the overall U.S. economy.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
This is pretty much exactly what you get when you have so much positive research.
One would need to use covered calls to initiate positions that provide a solid amount of downside protection.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
Let's review the charts and indicators.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
Let's look at the stocks that will get crushed and that you can't touch right now.
The company has worked on two previous coronavirus vaccines as well as an Ebola vaccine.
We can't wait for a vaccine, but we can follow logical guidelines for staying as safe as possible, helping us avoid another Great Depression.
Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.
It's not often you have both overnight and intraday gap risk, so be aware, and good luck out there.
Check out just a few of the year-to-date moves coming into Thursday on 8 companies you've never heard of before the last week or two.
As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.